Triamcinolone
| Evidence Level: L4 | Predicted Indications: 8 |
Table of Contents
Triamcinolone: Alopecia mucinosa
One-Sentence Summary
Triamcinolone is a corticosteroid, originally used for autoimmune and inflammatory conditions such as Crohn disease, adrenocortical insufficiency and eosinophilic pneumonia. The TxGNN model predicts it may be effective for alopecia mucinosa (follicular mucinosis), but there are no registered clinical trials and only 2 publications (both case reports, neither testing triamcinolone) behind this prediction. Evidence is limited to model prediction and indirect reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L4 (mechanistic rationale and case reports only; no direct triamcinolone evidence) |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, triamcinolone is a glucocorticoid. Its efficacy in inflammatory and autoimmune conditions is established, and mechanistically it may be applicable to alopecia mucinosa.
Follicular mucinosis involves a perifollicular inflammatory infiltrate and mucin deposition. Corticosteroids, including intralesional triamcinolone, have anti-inflammatory effects that could plausibly reduce this infiltrate. This is the only link between the original and predicted indications.
The supporting literature is thin. It consists of a 1964 case description and a 2014 case report of successful treatment with topical bexarotene gel, not triamcinolone. There is therefore no direct triamcinolone evidence for this condition in the data supplied.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23968145 | 2014 | Case report | Int J Dermatol | First reported case of topical bexarotene 1% gel successfully treating persistent idiopathic follicular mucinosis not associated with cutaneous T-cell lymphoma. Triamcinolone was not used. |
| 14170262 | 1964 | Case report | Hifuka Kiyo (Acta Dermatologica) | Case of alopecia mucinosa (Pinkus) / follicular mucinosis (Jablonska). No abstract available. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 2117K | Tricortone | Cream containing triamcinolone acetonide 200 micrograms per g, 100 g | Not available in the compiled data |
The only registered form is a topical cream. Whether it is suitable for follicular disease, where intralesional injection is the usual approach, has not been assessed.
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease links, not label text): hypertension, congestive heart failure, hyperglycaemia, liver disease, gallbladder disease, epilepsy, herpes simplex virus keratitis, measles, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia), and pituitary hormone deficiency conditions (hypopituitarism, growth hormone deficiency, hypogonadotropic hypogonadism, Kallmann syndrome, Sheehan syndrome).
- Drug Interactions: 100 interactions were identified. The most notable in the compiled sample is adalimumab (Major). Many others are Moderate, including zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alefacept, alemtuzumab and aliskiren, along with a tetanus toxoid vaccine. Formoterol and salbutamol are Minor.
Label warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The high model score (0.9999) is supported only by a plausible anti-inflammatory rationale and two case reports that do not involve triamcinolone. There are no trials. Label safety data are also missing, so the candidate cannot proceed to safety screening.
To proceed, the following is needed:
- Triamcinolone-specific clinical data in follicular mucinosis (case series or trials, with intralesional or topical use)
- Mechanism of action data
- TGA Product Information warnings and contraindications for the registered product
- Confirmation of the approved indication and route suitability for the ARTG-listed topical cream
- A review of the interaction profile, particularly with adalimumab
Other predicted indications: The data compiled for this report also cover nine further predictions. Folliculitis decalvans is the most developed (L3, two entries of a retrospective review of 23 patients, with a plausible role for intralesional or topical corticosteroids, though triamcinolone-specific efficacy is unconfirmed). Idiopathic steroid-sensitive nephrotic syndrome (L4) rests on class-level glucocorticoid evidence from two reviews. The remainder (telogen effluvium, alopecia antibody deficiency, hereditary hypotrichosis with recurrent skin vesicles, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, atrichia with papular lesions, alopecia universalis onychodystrophy vitiligo, and steroid-resistant nephrotic syndrome) are L5 and rated Hold. The steroid-resistant nephrotic syndrome prediction contradicts the definition of the condition.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.